Price
Target price
€11.40
€11.40
0.000%
-
0.000%
€17.04
13.03.26 / Frankfurt
WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Enanta Pharmaceuticals Inc. Stock
The Enanta Pharmaceuticals Inc. price is unchanged compared to yesterday.
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Enanta Pharmaceuticals Inc..
As a result the target price of 17 € shows a positive potential of 49.12% compared to the current price of 11.4 € for Enanta Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Enanta Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | 0.000% | -0.870% | -2.564% | 80.952% | -16.176% | -72.596% | -73.364% |
| Heron Therapeutics Inc. | -5.000% | -7.083% | -20.452% | -64.977% | -30.521% | -65.330% | -94.528% |
| Evolus Inc | 0.000% | -8.936% | 18.889% | -63.729% | -21.468% | -45.823% | -56.442% |
| Sangamo Therapeutics Inc. | -5.730% | 2.026% | 1.590% | -62.380% | -5.003% | -84.119% | -96.551% |
Comments
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
